<DOC>
	<DOCNO>NCT00087061</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gimatecan , work different way stop tumor cell divide stop grow die . PURPOSE : This phase I/II trial study side effect best dose gimatecan treating patient recurrent progressive primary malignant glioma .</brief_summary>
	<brief_title>Gimatecan Treating Patients With Recurrent Progressive Primary Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) gimatecan patient recurrent progressive primary malignant glioma treat without concurrent enzyme-inducing anticonvulsant drug . - Determine whether drug sufficient activity warrant development patient . ( phase II ) Secondary - Determine qualitative quantitative toxic effect drug patient . - Determine pharmacokinetic behavior drug patient . - Correlate principal toxic effect pertinent pharmacokinetic parameter drug patient . - Determine antitumor activity drug patient . OUTLINE : This open-label , dose-escalation , multicenter study . Patients stratify accord concurrent use enzyme-inducing anticonvulsant drug ( yes v ) . - Phase I : Patients receive oral gimatecan daily day 1-5 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos gimatecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive gimatecan phase I MTD . Patients follow least 1 month every 2 month thereafter . PROJECTED ACCRUAL : Approximately 30-83 patient ( 30-42 phase I [ 15-21 per stratum ] 21-41 phase II ) accrue study within 24 month .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant glioma ( glioblastoma multiforme , anaplastic astrocytoma , anaplastic oligodendroglioma ) Recurrent progressive primary CNS neoplasm contrastenhanced MRI Tumor progression prior surgery , radiotherapy , chemotherapy Measurable evaluable disease Failed prior standard curative palliative therapy ( phase I ) PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy At least 3 month Hematopoietic Absolute neutrophil count ≥ 2,000/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic SGPT SGOT ≤ 1.5 time upper limit normal ( ULN ) ( 3 time ULN liver metastasis present ) Alkaline phosphatase ≤ 2.5 time ULN ( 5 time ULN liver metastasis present ) Bilirubin normal Renal Creatinine ≤ 1.5 time ULN Cardiovascular No myocardial infarction past year No heart failure ( include cardiac insufficiency control digitalis diuretic ) No irreversible arrhythmia require permanent medication No uncontrolled hypertension Gastrointestinal No gastrointestinal dysfunction would alter absorption motility , follow : Active peptic ulcer Inflammatory bowel disease Known intolerance lactose Malabsorption syndromes Intestinal subocclusion Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No active infection No mentally incapacitate patient No concurrent severe disease would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) No 1 prior chemotherapy regimen No concurrent chemotherapy Endocrine therapy Concurrent corticosteroid allow dose stable past 2 week No concurrent hormonal therapy Radiotherapy See Disease Characteristics At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery See Disease Characteristics At least 3 week since prior surgical resection No prior gastrointestinal surgery would affect drug absorption Other More 4 week since prior participation investigational drug study More 72 hour since prior systemic antibiotic No concurrent H2 antagonist , antacid , proton pump inhibitor If therapy necessary , ≥ 3 hour must elapse gimatecan administration No concurrent anticancer therapy No concurrent investigational drug No concurrent immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>